BioCentury | Apr 7, 2021
Distillery Therapeutics

Toxin-derived YBX1 inhibitor for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer A YBX1 inhibitor derived from azopodophyllotoxin could treat ovarian cancer. In a panel of five human ovarian cancer cell lines, the compound inhibited growth with IC50 values of 1.27-6.8...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

Growth in China’s biotech sector has driven up demand for executives who can run companies with innovative therapies that can compete on a global stage. BioCentury’s analysis shows that while MNCs remain the primary breeding...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

FDA’s approval late Friday of Abecma idecabtagene vicleucel marks the second CAR T cell therapy BMS will bring to market as it continues to fill out its cancer portfolio ahead of revenue losses from...
BioCentury | Mar 19, 2021
Product Development

Self-amplifying may be the next frontier in RNA therapies

With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s...
BioCentury | Mar 15, 2021
Product Development

Alzheimer’s data from Lilly and Biogen converge on small effect for amyloid targeting

Emerging data from anti-amyloid therapies from Eli Lilly and Biogen continue to mirror each other. Whether the consistent findings will bolster both therapies’ cases with regulators, or whether the mAbs...
BioCentury | Feb 26, 2021
Distillery Therapeutics

FOXI1, CAII inhibition to treat tuberous sclerosis complex-associated kidney cysts

DISEASE CATEGORY: Renal INDICATION: Renal damage Targeting transcription factor FOXI1 or downstream target CAII, a cytoplasmic carbonic anhydrase, could treat kidney cysts associated with tuberous sclerosis complex, a genetic disorder caused by mutations in TSC1 or...
BioCentury | Feb 19, 2021
Product Development

Phase III Astellas readout marks step forward for non-hormonal menopause therapies

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy. Astellas Pharma Inc. (Tokyo:4503) said Friday the Phase III SKYLIGHT 1 and...
BioCentury | Feb 12, 2021
Regulation

FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients

Regeneron’s Evkeeza evinacumab-dgnb gained FDA approval Thursday as the first ANGPTL3 inhibitor to treat homozygous familial hypercholesterolemia, offering a new mechanism of action to patients who don’t respond to statins or PCSK9 therapy.  The mAb is approved as an adjunct...
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

The next stage of Incyte’s growth strategy is already well under way as the company continues to expand its cancer portfolio and prepares to bring its first dermatology program to market.  Much of the current...
Items per page:
1 - 10 of 1826